Pediatric Brain Cancer: UNC Pharmacy Team Advances Research Toward Treatment Breakthrough

Why Is Pediatric Brain Cancer So Difficult to Treat?

Brain and central nervous system tumors are the most common solid tumors in children and, according to the National Cancer Institute and the Children's Brain Tumor Foundation, now surpass leukemia as the leading cause of cancer-related death in pediatric patients. Tumors such as medulloblastoma, diffuse midline glioma, and ependymoma behave very differently from adult brain cancers, with distinct genetic drivers that many approved therapies do not target.

A central obstacle is the blood-brain barrier, a tightly regulated layer of endothelial cells that protects the brain but also blocks most chemotherapy drugs from reaching tumor tissue at therapeutic concentrations. Pharmacy researchers at UNC Chapel Hill's Eshelman School of Pharmacy are studying how drug formulation, nanoparticle delivery, and molecular design can help therapies cross this barrier without damaging surrounding healthy brain tissue — a critical concern in children whose brains are still developing.

What Role Does Pharmacy Research Play in Finding New Therapies?

Pharmacy-led oncology research bridges the gap between basic biology and bedside treatment. Teams at academic medical centers like UNC combine medicinal chemistry, pharmacokinetics, and pediatric pharmacology to adapt drugs originally developed for adults so they can be dosed safely and effectively in children. This is especially important in neuro-oncology, where tumor heterogeneity and developmental biology complicate treatment choices.

Recent approaches being explored in academic pharmacy labs include targeted nanoparticle carriers that release chemotherapy only inside tumor cells, convection-enhanced delivery that bypasses the blood-brain barrier entirely, and repurposing of existing drugs identified through high-throughput screening. The goal, researchers emphasize, is not only to extend survival but to reduce the severe long-term cognitive, endocrine, and developmental effects that current radiation and chemotherapy regimens can cause in pediatric survivors.

How Close Are We to a Real Treatment Breakthrough?

While the phrase "breakthrough" is often used cautiously in oncology, the landscape for pediatric brain cancer has shifted meaningfully over the past decade. The US Food and Drug Administration has approved targeted therapies for specific pediatric low-grade gliomas with BRAF mutations, and ongoing clinical trials registered on ClinicalTrials.gov are evaluating immunotherapies, CAR T-cell approaches, and novel small molecules in children.

Academic pharmacy programs contribute by generating preclinical evidence, optimizing pediatric formulations, and supporting investigator-initiated trials. Families and clinicians should look to organizations like the Children's Oncology Group, the Pediatric Brain Tumor Consortium, and their treating hospitals for information about current trial options, as enrollment in clinical studies remains one of the most important ways to access emerging therapies.